Peptide basics
One is approved but discontinued. The other is not a peptide
On this page
Enclomiphene has 19 verified registered trials enrolling 2,189 people and reached phase 3. It has no FDA-approved product.
Gonadorelin has 14 verified trials with 581 participants and two FDA approvals — both for products now discontinued.
Enclomiphene is not a peptide. Its formula is C26H28ClNO, and it belongs to the same chemical family as tamoxifen.
So one has evidence and no approval, the other has approvals nobody can fill, and only one of the two is what this directory is nominally about.
This page compares the public evidence and regulatory records of two compounds affecting the reproductive hormone axis. It is not medical advice, makes no recommendation, and contains no dose, schedule or route.
Enclomiphene is not a peptide
Its molecular formula is C26H28ClNO, with a chlorine atom and no repeating amide backbone. It is a selective oestrogen receptor modulator — the same class as tamoxifen and clomifene — and it is a small molecule, not a chain of amino acids.4
It appears in this directory because it is sold and discussed alongside peptides in the same channels, and leaving it out would mean not covering something people are actually looking up. Its page says what it is.4
The two records
Enclomiphene has 19 verified registered trials with 2,189 participants and reached phase 3, without an approval following. Gonadorelin has 14 trials with 581 participants, reached phase 4, and holds approvals for LUTREPULSE KIT and FACTREL — both recorded as discontinued.123
So the compound with more evidence has never been approved, and the compound with approvals has products nobody is selling. Neither is available as an approved medicine today.13
What phase 3 without approval means here
Enclomiphene's programme reached the stage where large confirmatory trials run. No approval followed, and the registry does not record why. As always, that can reflect the results or the sponsor's circumstances.1
What can be said is that 2,189 people received it under registered protocols, which is more human evidence than most compounds tracked here have, and that no regulator has authorised a product containing it.1
Common questions
Why include a non-peptide in a peptide directory?
Because it is sold and searched alongside them. Excluding it would leave a gap where readers are actually looking, and its page states plainly that it is not a peptide.
Can gonadorelin be obtained if its products are discontinued?
Not as those approved products. Anything sold under the name outside the regulated supply chain is not covered by those approvals in any respect.
Does 2,189 participants make enclomiphene well established?
It is a substantial record by the standards of this site and it did not result in an approval. Both facts belong in any summary of it.
Sources
- RegulatoryClinicalTrials.gov search — intervention: enclomipheneU.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=enclomiphene ↗↩ Back to text
- RegulatoryClinicalTrials.gov search — intervention: gonadorelinU.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=gonadorelin ↗↩ Back to text
- RegulatoryDrugs@FDA — gonadorelin approval records (LUTREPULSE KIT, FACTREL)U.S. Food and Drug Administration, 2026www.accessdata.fda.gov/scripts/cder/daf/ ↗↩ Back to text
- RegulatoryPubChem — enclomiphene, formula C26H28ClNONational Center for Biotechnology Information, 2026pubchem.ncbi.nlm.nih.gov/ ↗↩ Back to text